e.g. mhealth
Search Results (1 to 3 of 3 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Formative Research
- 1 JMIR Research Protocols
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Previous studies have demonstrated the efficacy of amiodarone in reducing the occurrence of VF after the removal of the ACC [11,12]. However, there is only 1 clinical trial investigating the role of amiodarone in reducing r VF in patients with LVH [13]. Therefore, we designed the study to investigate the effects of prophylactic intravenous amiodarone on r VF after the release of the ACC in patients with LVH undergoing open-heart surgery.
JMIR Form Res 2025;9:e64586
Download Citation: END BibTex RIS
Patients older than 18 years who had first been prescribed oral amiodarone between January 2005 and December 2017 were included. Patients were excluded if they were pregnant or had a history of a thyroid disorder diagnosis, thyroid surgery, or subclinical thyroid laboratory data (Multimedia Appendix 1) within 1 year before the index day, which was the day of the first amiodarone prescription.
J Med Internet Res 2023;25:e43734
Download Citation: END BibTex RIS
Amiodarone is a class III antiarrhythmic agent with multiple electrophysiological effects, which has been used clinically in the management of both atrial and ventricular arrhythmias. Through hepatic metabolism, amiodarone is transformed to desethylamiodarone, which has the property of antiarrhythmic effects. Amiodarone is highly lipid soluble and is widely stored in fat, muscle, skin, liver, and lungs with a very long elimination half-life, averaging about 58 days [21].
JMIR Res Protoc 2023;12:e40115
Download Citation: END BibTex RIS